2019 Executive Sponsors

Mitra Biotech

2018 Executive Sponsors

IsoPlexis
Mitra Biotech

2018 Associate Sponsors

Adaptive Biotechnologies
BeiGene
Compass Therapeutics
Exicure
Inovio
Iovance
nanoString Technologies
Personalis

2018 Supporting Sponsors

Biodesix
Neon Therapeutics

2018 Educational & Supporting Partners

CRI
SITC
Solebury Trout

2018 Media Partners

Clinical Leader
Life Science Leader
pharmaphorum
SciDoc Publishers
STAT news
Technology Networks

Overview

Lead advisors Dr Patrick Hwu, MD Anderson, Dr Axel Hoos, GSK and Dr Ian McCaffery, Janssen, presented the 3rd annual Rational Combinations 360° program that addressed business aspects, clinical advancements and scientific data in IO combination strategies. The rapid advancement in our understanding of human cancer immunity and immunotherapy combinations is nearly impossible for individual scientists to comprehend. Only together, as an engaged and interactive scientific community, can we hope to enable a patient’s immune system to eradicate cancer.

The Rational Combinations 360° summit will return to Philadelphia in September 2019. Check back this Spring for more program announcements.  

2018 Featured Speakers

What to Expect at Rational Combinations 360° 2018 – 5 Mins Overview

 

Rational Combinations 360° addressed the following:

  September 13, 2018

  Discovery and Preclinical Science

  • IO Combinations with CAR-T Therapies
  • Preclinical Data on BiTE Platform and Associated Combinations
  • The Tumor Explant Model as a Model System to Understand Treatment Effects
  • Model Systems for Studying Combinations
  • Single Cell Sequencing and Mechanisms of Immuno-Resistance
  • Prioritizing Combinations using a Human Phenotypic Model for Drug Development

  Translational Science and Emerging Biomarkers

  • The Role of the Gut Microbiome in Response to Immunotherapy
  • IO Combinations Based on Tumor Mutation Analysis
  • TCR Sequencing as a Predictive Biomarker of Response in IO
  • Advanced Analytics Combining Augmented Exome and Transcriptome Sequencing for Neoantigen Identification and Novel Biomarker Discovery
  • Synergy Mechanisms Between Combination Immunotherapies Using Single Cell Proteomics

  Operationalizing IO Combinations

  • Novel Platform Trial Designs for IO Combinations
  • Regulatory Framework for Investigating & Approving Combinations
  • Biomarker Procurement for IO Combinations
  • The Operational Challenges of IO Combination Trials

  IO Emerging Technologies

 

  September 14, 2018

  Emerging Clinical Combinations

  • PD-1 Antibody Based Immuno-oncology Novel Combinations Across Indications
  • Immunotherapy Combinations with Parp Inhibitors
  • Overcoming the Resistance to Immune Checkpoint inhibitors via Rational Combination of Immunotherapy
  • IDO Inhibition Combination Trial Perspectives: Epacadostat + Pembrolizumab for Melanoma

  Emerging Data Combinations in Clinical Trials

  • Novel Approaches to Engineered Cancer Immunotherapy
  • Lymphocytes as a Drug for the Treatment of Metastatic Cancer
  • Update on IMPower150 in Lung Cancer
  • Addressing Clinical Combination Challenges

  Business Aspects

  • IO Combination Deals and Partnerships
  • Investment Strategies Driving IO Combinations
  • Assessing Value & Market Access Implications of Immuno-Oncology Combination Therapies

  
Rational Combinations 360° provided the most up-to-date research, data and progress on combination developments to help IO stakeholders:

  • Be at the forefront of the most relevant research and developments for IO combinations from key leadership who are at the pulse of cancer immunotherapy
  • Foster collaboration amongst others working in all aspects of cancer immunotherapy by rounding up all stakeholders under one roof
  • Receive the latest pre-clinical, translational and clinical data from academia and industry
  • Better understand what assets are available for potential combinations that may be able to give patients more treatment options
  • Create and prioritize combination strategies targeted toward specific tumor types
  • Get key investor and analyst evaluations and insights on the IO combination landscape
  • Learn about biomarker advancements, neoantigen approaches and more
  • Obtain coverage on a wide range of emerging technologies

If you are interested in participating in the 4th annual Rational Combinations 360° program, please contact Kate Woda at Kate@tcfllc.org.

Don’t wait until next September to continue the conversation of IO Rational Combinations. Join us at the 5th annual Immuno-Oncology 360° Summit February 6-8, 2019 in NYC. Learn more here.

Sincerely,

Kate-BW-2

Kate Woda
Conference Director

Valerie Bowling New

Valerie Bowling
Executive Director

Meredith-2018

Meredith Sands
Executive Director, Business Development

Elizabeth Bard B&W-47

Elizabeth Bard
Business Development Manager

geeta-new-bw

Geeta Bachani
Business Development Manager

Meg

Meg Gould
Conference Planner

Margaret Van Cleve
Associate Marketing Manager

Jenny O’Dea
Conference Coordinator


Testimonials

  • "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

    - Roy Baynes, Merck Research Labs

  • "I absolutely enjoyed the meeting! It was great getting both academia and industry together to discuss how we move forward."

    - Robert Andtbacka, Huntsman Cancer Institute

  • "Thanks so much for putting on a great conference. It was very informative and I was excited to be a part of it. I am looking forward to the next one!"

    - Amanda Bruno, GSK

  • "It was a great conference. I learned a lot and enjoyed the diversity of speakers"

    - Julia Keith, RA Capital

  • "It was great meeting. I really enjoyed the conference and my interactions with several of the participants."

    - Jeffrey Wallin, Genentech